BLRX - BioLineRX anti-tumor vaccine shows promise in early-stage trial
- AGI-134, an intratumoral cancer vaccine candidate from BioLineRX ( NASDAQ: BLRX ), demonstrated safety and tolerability in a phase 1/2a trial .
- In the accelerated dose-escalation part of the study, there were no dose-related toxicities reported. In the dose expansion portion, treatment-related adverse events were transient and for the most part, mild to moderate.
- BioLineRX ( BLRX ) also said that seven of the 11 patients who achieved stable disease had previously failed on a checkpoint inhibitor.
- Seeking Alpha's Quant Rating views BioLineRX ( BLRX ) as a hold with high marks for valuation and revisions .
For further details see:
BioLineRX anti-tumor vaccine shows promise in early-stage trial